PDF(Pubmed)
Abstract：
UNASSIGNED: This study is to highlight the incidence of corneal pseudomicrocysts in FDA-approved antibody-drug conjugates (ADCs), and success of preventive therapies for pseudomicrocysts and related ocular surface adverse events (AEs).
UNASSIGNED: ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity.
UNASSIGNED: Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.
UNASSIGNED: ADCs are an emerging class of selective cancer therapies that consist of a potent cytotoxin connected to a monoclonal antibody (mAb) that targets antigens expressed on malignant cells. Currently, there are 11 FDA-approved ADCs with over 164 in clinical trials. Various AEs have been attributed to ADCs, including ocular surface AEs (keratitis/keratopathy, dry eye, conjunctivitis, blurred vision, corneal pseudomicrocysts). While the severity and prevalence of ADC-induced ocular surface AEs are well reported, the reporting of corneal pseudomicrocysts is limited, complicating the development of therapies to prevent or treat ADC-related ocular surface toxicity.
UNASSIGNED: Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.
摘要：
■这项研究旨在强调FDA批准的抗体-药物偶联物（ADC）中角膜假微囊肿的发生率，假微囊肿和相关眼表不良事件（AE）的预防性治疗的成功。
■ADC是一类新兴的选择性癌症疗法，其由与靶向在恶性细胞上表达的抗原的单克隆抗体（mAb）连接的有效细胞毒素组成。目前,有11个FDA批准的ADC，临床试验中超过164个。各种AE都归因于ADC，包括眼表AEs（角膜炎/角膜病变，干眼症,结膜炎,视力模糊,角膜假微囊肿）。虽然ADC诱导的眼表AE的严重程度和患病率已得到充分报道，角膜假微囊肿的报告是有限的，使预防或治疗ADC相关眼表毒性的疗法的开发复杂化。
■11个FDA批准的ADC中有3个与角膜假微囊肿有关，发病率为41％至100％的患者。在报告眼表不良事件的六个ADC中，只有三个人进行了眼部治疗，以研究包括局部类固醇在内的预防性治疗的益处，血管收缩剂,和无防腐剂的润滑剂。目前的预防性治疗在减轻假微囊肿和其他眼表AE方面表现出有限的功效。
■ADC是一类新兴的选择性癌症疗法，其由与靶向在恶性细胞上表达的抗原的单克隆抗体（mAb）连接的有效细胞毒素组成。目前,有11个FDA批准的ADC，临床试验中超过164个。各种AE都归因于ADC，包括眼表AEs（角膜炎/角膜病变，干眼症,结膜炎,视力模糊,角膜假微囊肿）。虽然ADC诱导的眼表AE的严重程度和患病率已得到充分报道，角膜假微囊肿的报告是有限的，使预防或治疗ADC相关眼表毒性的疗法的开发复杂化。
■11个FDA批准的ADC中有3个与角膜假微囊肿有关，发病率为41％至100％的患者。在报告眼表不良事件的六个ADC中，只有三个人进行了眼部治疗，以研究包括局部类固醇在内的预防性治疗的益处，血管收缩剂,和无防腐剂的润滑剂。目前的预防性治疗在减轻假微囊肿和其他眼表AE方面表现出有限的功效。
